Interferon gamma human recombinant
Pharmaclone
23 Items
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Ingaron has antiviral, immunomodulatory effects.
Indications
Combined therapy: chronic viral hepatitis C, chronic viral hepatitis B, HIV / AIDS infection, pulmonary tuberculosis, oncological diseases (as an immunomodulator - including in combination with chemotherapy) herpes zoster (Herpes zoster) - in monotherapy. Prevention of infectious complications in patients with chronic granulomatous disease.
Composition
1 bottle contains interferon gamma 500 thousand ME.
No customer reviews for the moment.
Dosage and Administration
IM, SubQ. The contents of the vial are dissolved in 2 ml of water for injection. Dose Ingaron set individually. Typically, the average daily dose for adults is 500 thousand ME. Entered 1 time per day, every day or every other day. For the course - 5-15 injections, if necessary, prolong the course or repeat after 10-14 days.
Adverse reactions
Ingaron is a lyophilisate for preparing a solution for intramuscular and subcutaneous administration: local pain in the site of s / c administration in the form of weak breaking pain (like overtrained muscle) and hyperemia. Use of doses over 1 million ME may be accompanied by the development of flu-like syndrome: headache, weakness, fever, joint pain. Mild symptoms do not require pharmacological correction. In severe cases, paracetamol is relieved.
Ingaron lyophilisate for preparation of the solution for intranasal administration: none.
Contraindications
individual intolerance to interferon gamma or any other component of the drug; pregnancy. Lyophilisate for preparation of a solution for intramuscular and subcutaneous administration: autoimmune diseases; diabetes mellitus. Lyophilisate for preparation of a solution for intranasal administration: children (under 7 years of age).
- Brand name: Ingaron
- Active ingredient: Interferon gamma human recombinant
- Dosage form: Lyophilisate for preparation of solution for intranasal administration.
- Manufacturer: Pharmaclone
- Country of Origin: Russia
Studies and clinical trials of Interferon gamma human recombinant (Click to expand)
- Monitoring recombinant human interferon-gamma N-glycosylation during perfused fluidized-bed and stirred-tank batch culture of CHO cells
- Inhibition of interleukin-1-induced collagenase production in human articular chondrocytes in vitro by recombinant human interferon-gamma
- Therapy of chronic hepatitis b with recombinant human alpha and gamma interferon
- Effects of recombinant human interferon-alpha, beta and gamma on the antiproliferative activity of cytarabine in K562 human myeloid leukemia clonogenic cells
- Recombinant human interferon gamma suppresses HTLV-III replication in vitro
- Synergism of recombinant human interferon gamma with liposome-encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes
- Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma
- Recombinant interferon alpha and gamma modulate the invasive potential of human melanoma in vitro
- Mechanism of interaction between cisplatin and human recombinant interferon gamma in human ovarian-cancer cell lines
- Inhibitory effects of nicotinamide on recombinant human interferon-gamma-induced intercellular adhesion molecule-1 (ICAM-1) and HLA-DR antigen expression on cultured human endothelial cells
- Quantitative modifications of major histocompatibility complex (MHC) antigens induced by recombinant gamma interferon in two human breast cancer lines
- Chromatographic refolding of recombinant human interferon gamma by an immobilized sht GroEL191-345 column
- Efficient activation of human blood monocytes to a tumoricidal state by liposomes containing human recombinant gamma interferon
- Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives
- Recombinant gamma interferon induces HLA-DR expression on squamous cell carcinoma, trichilemmoma, adenocarcinoma cell lines, and cultured human keratinocytes
- Tryptophan reversal of recombinant human gamma-interferon inhibition ofChlamydia trachomatisgrowth
- A Phase II combination trial with recombinant human tumor necrosis factor and gamma interferon in patients with colorectal cancer
- Sensitivity of chronic myeloid leukemia hemopoietic progenitors to PTT-119 in combination with human recombinant interferon alpha and gamma
- Recombinant human interferon-gamma in patients with chronic granulomatous disease —European follow up study
- Construction and identification of the recombinant of the AAV vector and human interferon-gamma
- Coexpression of chaperonin GroEL/GroES markedly enhanced soluble and functional expression of recombinant human interferon-gamma inEscherichia coli
- Kinetic studies of recombinant human interferon-gamma expression in continuous cultures ofE. coli
- Pilot study of human recombinant interferon gamma and accelerated hyperfractionated thoracic radiation therapy in patients with unresectable stage IIIA/B nonsmall cell lung cancer
8 other products in the same category:
arrow_upward